BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death. (31st May 2018)

• Record Type: Journal Article
• Authors: Stewart, Helen J. S.; Chaudry, Sabah; Crichlow, Asante; Luiling Feilding, Freya; Chevassut, Timothy J. T.
• Other Names: Porrata Luis F. Academic Editor.
• Is Part Of: Bone marrow research. Volume 2018(2018)
• Publication Date: 2018-05-31
• Subjects: Bone marrow -- Periodicals; 616.41
• DOI: 10.1155/2018/5742954
• Languages: English
• ISSNs: 2090-2999

Abstract

Abstract : S100A8 and S100A9 are both members of the S100 family and have been shown to play roles in myeloid differentiation, autophagy, apoptosis, and chemotherapy resistance. In this study we demonstrate that the BET-bromodomain inhibitor JQ1 causes rapid suppression of S100A8 and S100A9 mRNA and protein in a reversible manner. In addition, we show that JQ1 synergises with daunorubicin in causing AML cell death. Daunorubicin alone causes a dose- and time-dependent increase in S100A8 and S100A9 protein levels in AML cell lines which is overcome by cotreatment with JQ1. This suggests that JQ1 synergises with daunorubicin in causing apoptosis via suppression of S100A8 and S100A9 levels.